America's drug daze

Only a sliver of India's pharmaceutical exports to the US, placed at roughly $10.5 billion in 2024-25, appears to face the 100% tariff hurdle likely to be erected this week by American President Donald Trump.

- 

Since the vast bulk of what we export are generic drugs, rather than patented or branded ones, this is not a crisis for our pharma industry. The new tariff's exact targets await clarity, but unless the term “branded” somehow gets stretched to cover trademark-bearing products that command no prem